Detecting Cancer Burden in Liquid Biopsies
15 September 2016

Liquid biopsy is a non-invasive sample source that can be utilized to assess cancer burden by measuring the tumor-derived fraction of circulating, cell-free DNA (cfDNA) from plasma. The study detailed on this poster evaluates two methods to monitor cancer burden using cfDNA: whole genome bisulfite sequencing (WGBS) and targeted amplicon sequencing for 56 oncology-related genes.